Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Vir Biotechnology, Inc. (NASDAQ:VIR) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $16.00.

Several brokerages have recently issued reports on VIR. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Barclays reiterated an “overweight” rating and issued a $24.00 price objective on shares of Vir Biotechnology in a report on Wednesday, February 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of Vir Biotechnology in a report on Monday, February 9th.

Vir Biotechnology Price Performance

Shares of VIR opened at $7.47 on Tuesday. The company has a 50-day simple moving average of $6.65 and a two-hundred day simple moving average of $5.86. The firm has a market capitalization of $1.04 billion, a PE ratio of -2.07 and a beta of 1.69. Vir Biotechnology has a one year low of $4.16 and a one year high of $10.01.

Insider Activity

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of Vir Biotechnology stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.98, for a total transaction of $1,147,286.92. Following the completion of the transaction, the insider owned 13,728,924 shares in the company, valued at approximately $82,098,965.52. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $7.71, for a total value of $169,620.00. Following the completion of the sale, the director directly owned 1,144,391 shares in the company, valued at $8,823,254.61. This trade represents a 1.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 911,059 shares of company stock worth $5,699,389 in the last three months. 16.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new stake in Vir Biotechnology during the second quarter valued at approximately $35,000. FNY Investment Advisers LLC purchased a new position in shares of Vir Biotechnology during the 3rd quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after acquiring an additional 1,390 shares during the period. UMB Bank n.a. increased its stake in shares of Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after purchasing an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares during the period. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.